The FDA peptide vote, and why it changes almost nothing

This is the written version of Explained: FDA Peptide Vote — Ban or Legalise? — watch it on the channel, or read on.

Half the internet was dead certain the FDA was about to ban your favourite peptide forever. The other half was throwing a party because it was all being legalised. Both camps were staring at the same two-day meeting, in the same conference room in Silver Spring, with the same institutionally terrible coffee. Both of them were wrong.

I'm a chartered chemical process engineer, which mostly means I get paid to read boring government documents so you don't have to. I read the briefing pack before the meeting — that's the video above, filmed the week before the vote — and I've read what came out of it since. So here is the honest version, as of late July 2026: what the committee was, what it actually decided on the 23rd and 24th, and why the answer to “so is it legal now?” is still, annoyingly, “no, and not for a while.”

The approved chemicals list at the plant gate

Every chemical plant I have ever worked on has a storeroom and a master list of approved ingredients — the stuff the site is officially allowed to keep on the shelf and work with. If it is not on that list, it does not come through the gate. Doesn't matter how good the sales rep was.

The 503A bulk drug substances list is exactly that, but for compounding pharmacies — the pharmacies that mix a medicine to order for one patient on one prescription. Under FDA's interim policy, Category 1 means a compounder may work with the substance while the paperwork grinds on. Category 2 means FDA has identified significant safety risks and would consider taking action against a compounder who used it. Category 3 means nobody sent in enough information to judge — try again.

Now here is the bit both camps miss, and I want you to write it down: being on the approved list is not the FDA certifying that something is safe and effective. It is not an approval. No proven dose, no guaranteed benefit, no promise it does anything at all. The storeroom list only says a pharmacist is allowed to keep the drum on the shelf. It says nothing whatsoever about whether what is in the drum will do a thing for you.

How we got here: three dates that are not the same event

The “ban” thread starts in September 2023, when FDA placed more than a dozen peptides — BPC-157 among them — into Category 2, citing immunogenicity risk and thin human data. Worth a correction to what I said on camera: those peptides were not demoted from Category 1. They had been nominated and were sitting in the queue. Category 2 was where they landed, not where they fell from. Either way: benched.

The “legalised” thread starts on 27 February 2026, when the Department of Health and Human Services announced its intention to move roughly 14 of 19 restricted peptides back toward Category 1. That is the party the second camp is still throwing. An announcement of intent is a memo. It is not a rule.

Then on 15 April 2026, FDA actually removed twelve substances from the Category 2 list. Which sounds like the finish line and absolutely is not. Coming off the “do not compound” list does not put you on the “may compound” list. It takes you out of the penalty box and puts you back in the queue. Closing that gap is what 23 and 24 July was for.

What the committee actually decided

Two days, seven peptides, seven votes on whether to recommend adding each one to the 503A list. Here is how they fell.

• BPC-157 — recommended, 8 to 6
• KPV — recommended, 8 to 6
• TB-500 — recommended, 8 to 6
• MOTS-c — recommended, 7 to 5
• Semax — recommended, 8 to 5
• Epitalon — recommended, 7 to 4
• Emideltide, the compound most people know as DSIP — rejected, 6 to 7

Six out of seven, and DSIP the only no of the meeting. Look at those margins, though. Nothing here was a landslide. One or two people changing their mind flips half of them. This was a room that argued.

Here's the catch: the committee voted against the FDA's own reviewers

FDA's scientific review team wrote a briefing document for each of the seven substances, and recommended against adding every single one of them. The committee overruled that on six. The reviewers' objections came in three buckets, and they are worth understanding, because a vote does not answer any of them.

What is it? This is the characterisation problem, and as an engineer it is the one that genuinely stings. FDA's reviewers said BPC-157 is not adequately characterised — inconsistent naming that does not follow established chemical nomenclature, and gaps in the data needed to pin down identity, purity and quality. One FDA staffer put it as bluntly as you can put anything in a federal advisory meeting: what is BPC-157? You cannot write a specification for a material you cannot define. No specification, no quality standard. No quality standard and the drum arriving at the gate is just a white powder with a confident label.

Does it work? On effectiveness, the reviewers' evaluation of BPC-157 for ulcerative colitis turned up essentially one small clinical trial, reported in a meeting abstract, using a route of administration that is not the one people actually use. For KPV, reviewers reported finding no human studies at all in their evaluation.

Is it safe? Immunogenicity — your immune system learning to recognise and attack a peptide — plus the risk from peptide-related impurities, both of which get worse when something is injected rather than swallowed. For epitalon, reviewers additionally flagged a potential carcinogenicity signal and an absence of published efficacy data in the condition under review.

None of that has been resolved. A committee voting yes does not generate data.

Why six thumbs up changed nothing on Monday morning

A committee vote is a recommendation about what a pharmacist may keep on the shelf. It is not evidence, and it is not law.

The vote is non-binding advice. FDA does not have to take it — the agency usually lands in the same place as its advisers, but not always, and here its own reviewers are on the other side of the argument. And even where FDA agrees, actually putting a substance on the 503A list runs through notice-and-comment rulemaking: a proposed rule published in the Federal Register, a public comment window that typically runs 60 to 90 days, the agency reading and responding to every substantive comment, then a final rule. Realistic timeline, start to finish: somewhere in the region of one to two years.

Which is why the morning of 25 July looks exactly like the morning of 22 July. Same legal status. Same gray market. Same anonymous “trust me, bro” supply chain that nobody in that conference room has any authority over. That was the twist I promised at the top of the video, and it survived the meeting entirely intact.

One genuinely open question remains: whether FDA offers some form of interim position for these substances while rulemaking runs, rather than leaving them in limbo. As of late July 2026 that is undecided, and no proposed rule has appeared. This article reflects where things stand right now — if a proposed rule lands, the picture moves.

The bottom line

It was not a ban and it was not a green light. It was an advisory committee making non-binding recommendations about which substances pharmacies may be allowed to keep on the shelf — six yes, one no, all of them narrow, all of them against the advice of the FDA's own scientists — and every one of those recommendations still has to survive the agency and a year or more of rulemaking. Anyone selling you “banned forever” or “now legal” is selling you a headline, not the truth.

And notice what none of this changed. Not one word of it tells you that a single one of these peptides is safe, effective, or right for you. That part has not moved an inch. Regulatory status and real evidence are two different questions, and the loudest voices on both sides of this story have a strong commercial interest in you blurring them. Don't. Keep safe, keep skeptical.

Sources

1. FDA, July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee (agenda and briefing materials), 2026 — https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
2. FDA, PCAC Briefing Document: BPC-157 (free base) and BPC-157 acetate, 2026 — https://www.fda.gov/media/193343/download
3. FDA, Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (interim policy categories and rulemaking), 2026 — https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
4. FDA, Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (Category 2 list) — https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
5. Hyman, Phelps & McNamara (FDA Law Blog), PEPTIDE-L WAVE! PCAC Approves Four Bulk Drug Substances for the 503A List, July 2026 — https://www.thefdalawblog.com/2026/07/peptide-l-wave-pcac-approves-four-bulk-drug-substances-for-the-503a-list/
6. STAT News, FDA advisory panel narrowly rejects compounding of one peptide, backs two others, 24 July 2026 — https://www.statnews.com/2026/07/24/fda-peptide-compounding-panel-backs-epitalon-rejects-emideltide/
7. Fierce Pharma, Peptide adcomm Day 2: Emideltide voted down in panel's first peptide pushback, July 2026 — https://www.fiercepharma.com/pharma/peptide-adcomm-day-2-emideltide-voted-down-panels-1st-peptide-pushback
8. Orrick, FDA Peptide Compounding Vote: What to Watch at the July PCAC Meeting (rulemaking mechanics and timeline), July 2026 — https://www.orrick.com/en/Insights/2026/07/FDA-Peptide-Compounding-Vote-What-to-Watch-at-the-July-PCAC-Meeting

Educational and research purposes only — not medical advice. Peptide Corner does not recommend any vendor, source, or dose. Keep safe, keep skeptical.